Two Sigma Securities
IBO

Two Sigma Securities’s Impact BioMedical IBO Stock Holding History

Two Sigma Securities’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,798
Closed -$11.5K – 2322
2025
Q4 		$11.5K Sell
1,798
-456
-20% -$3.04K ﹤0.01% 1273
2025
Q3 		$18.9K Buy
+2,254
New +$17.9K ﹤0.01% 1148

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Mason & Associates (California)
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Two Sigma Securities's IBO Position: Q1 2026 in Review

Two Sigma Securities sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 1,798 shares — an estimated $11.5K sold.

Two Sigma Securities first reported a position in IBO in Q3 2025 and held it in 2 quarters. The position peaked at $18.9K in Q3 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Two Sigma Securities reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 1,798 Impact BioMedical shares in Q1 2026, an estimated $11.5K.
  • Two Sigma Securities first reported a position in Impact BioMedical in Q3 2025 and held it in 2 quarters.
  • Two Sigma Securities's Impact BioMedical position peaked at $18.9K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.